453
Participants
Start Date
May 29, 2020
Primary Completion Date
August 21, 2023
Study Completion Date
October 31, 2025
Tislelizumab
administered via Intravenous (IV) injection
Cisplatin injection
administered via IV infusion
Paclitaxel injection
administered via IV infusion
Pemetrexed Disodium
administered via IV infusion
Placebos
Placebo to match tislelizumab IV infusion
Carboplatin
administered via IV infusion
Peking University Peoples Hospital, Beijing
Beijing Friendship Hospital, Capital Medical University, Beijing
Xuanwu Hospital Capital Medical University, Beijing
Beijing Cancer Hospital, Beijing
Beijing Hospital, Beijing
Peking Union Medical College Hospital, Beijing
Liaoning Cancer Hospital and Institute, Shenyang
Jilin Cancer Hospital, Changchun
The First Hospital of Jilin University, Changchun
Harbin Medical University Cancer Hospital, Harbin
Fudan University Shanghai Cancer Center, Shanghai
Shanghai Chest Hospital, Shanghai
Affiliated Zhongshan Hospital of Fudan University, Shanghai
Shanghai Pulmonary Hospital, Shanghai
Nanjing Drum Tower Hospital,the Affiliated Hospital of Nanjing University Medical School, Nanjing
Anhui Provincial Hospital, Hefei
Tianjin Medical University General Hospital, Tianjin
Tianjin Medical University Cancer Institute and Hospital, Tianjin
The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou
The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou
Zhejiang Cancer Hospital, Hangzhou
Hwa Mei Hospital, University of Chinese Academy of Sciences (Ningbo No Hospital), Ningbo
The First Affiliated Hospital of Nanchang University Branch Donghu, Nanchang
The First Affiliated Hospital of Nanchang University Branch Xianghu, Nanchang
Fujian Medical University Union Hospital, Fuzhou
Fujian Cancer Hospital, Fuzhou
The First Affiliated Hospital of Xiamen University, Xiamen
Quanzhou First Affliated Hospital of Fujian Medical University, Quanzhou
Hunan Cancer Hospital, Changsha
Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan
Hubei Cancer Hospital, Wuhan
Luoyang Central Hospital, Luoyang
Cancer Center of Guangzhou Medical University, Guangzhou
Sun Yat Sen University Cancer Center, Guangzhou
Cancer Hospital of Shantou University Medical College, Shantou
Jiangmen Central Hospital, Jiangmen
The Tumor Hospital Affiliated to Guangxi Medical University, Nanning
Hainan Cancer Hospital, Haikou
Sichuan Cancer Hospital and Institute, Chengdu
West China Hospital, Sichuan University, Chengdu
Yunnan Cancer Hospital, Kunming
The First Affiliated Hospital of Xian Jiaotong University, Xi'an
General Hospital of Ningxia Medical University, Yinchuan
First Hospital of Shanxi Medical University, Taiyuan
Lead Sponsor
BeiGene
INDUSTRY